MethoCult™ H4034 Optimum
Methylcellulose-based medium with recombinant cytokines for human cells
Request Pricing
Thank you for your interest in this product. Please provide us with your contact information and your local representative will contact you with a customized quote. Where appropriate, they can also assist you with a(n):
Estimated delivery time for your area
Product sample or exclusive offer
In-lab demonstration
By submitting this form, you are providing your consent to STEMCELL Technologies Canada Inc. and its subsidiaries and affiliates (“STEMCELL”) to collect and use your information, and send you newsletters and emails in accordance with our privacy policy. Please contact us with any questions that you may have. You can unsubscribe or change your email preferences at any time.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Overview
Data Figures
Protocols and Documentation
Find supporting information and directions for use in the Product Information Sheet or explore additional protocols below.
Applications
This product is designed for use in the following research area(s) as part of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we offer to support each research area.
Resources and Publications
Educational Materials (19)
Frequently Asked Questions
Publications (41)
Inhibition of inflammation and senescence with azole compound C7 enables expansion of hematopoietic stem and progenitor cells.
Stem cells translational medicine 2026 Jun
Abstract
Human hematopoietic stem and progenitor cells (HSPCs) derived from umbilical cord blood (UCB) are often insufficient in quantity for transplantation, necessitating efforts for ex vivo expansion. We previously developed a novel azole-based small molecule, C7, as a structural analog of the p38 mitogen-activated protein kinase inhibitor SB203580. C7 mediated robust ex vivo expansion of UCB HSPCs from unselected mononuclear cells, compared to its structural analogs and other published compounds. However, the molecular underpinnings of C7's potency remained unclear. In this work, we demonstrate that C7 preferentially enhances the proliferation and viability of early HSPC subsets upon direct culture with pre-isolated HSPCs, while limiting mitochondrially-derived reactive oxygen species production linked to oxidative stress. C7 treatment enhances hematopoietic stem cell self-renewal and in vivo multilineage reconstitution without T- or myeloid lineage bias. Unlike existing p38 inhibitors, C7 targets multiple kinases and pathways to achieve superior HSPC expansion through suppression of NFκB and IL-10 inflammatory signaling and attenuation of stress/senescence‑associated markers (eg, SERPINB2 and CDKN1A/p21). This mechanism of action of C7 is distinct from those of other existing compounds used for ex vivo HSPC expansion and has implications for application in other ex vivo culture platforms and clinical settings.
A porcine model of Fanconi anemia
PLOS One 2025 Oct
Abstract
Although small animal models of Fanconi anemia (FA) are useful, they do not faithfully replicate many of the clinical features seen in FA patients. We reasoned that a porcine model of FA with its similar physiology and a relatively long lifespan would produce a phenotype more similar to human FA. Targeting FANCA in domestic swine resulted in skeletal abnormalities and extreme sensitivity to interstrand DNA cross-linking agents. In addition, FANCA disruption followed by mitomycin C treatment resulted in a > 10-fold increase in chromosomal radials, a finding that is considered diagnostic for human FA. Bone marrow derived, hematopoietic progenitor cells from a FANCA null pig showed a 75% reduction in colony forming activity compared to wild type. Evaluation of steady state hematopoiesis in the peripheral blood revealed the gradual development of red cell macrocytosis and a reduction in circulating neutrophils. Targeting of FANCD2 failed to produce any biallelic animals demonstrating the loss of FANCD2 function is embryonic lethal in pigs. These results indicate that a porcine model of FANCA holds promise for the development of strategies to prevent the development of bone marrow failure and malignancies in patients with FA.
Continuous map of early hematopoietic stem cell differentiation across human lifetime
Nature Communications 2025 Mar
Abstract
Uncovering early gene network changes of human hematopoietic stem cells (HSCs) leading to differentiation induction is of utmost importance for therapeutic manipulation. We employed single cell proteo-transcriptomic sequencing to FACS-enriched bone marrow hematopoietic stem and progenitor cells (HSPCs) from 15 healthy donors. Pseudotime analysis reveals four major differentiation trajectories, which remain consistent upon aging, with an early branching point into megakaryocyte-erythroid progenitors. However, young donors suggest a more productive differentiation from HSPCs to committed progenitors of all lineages. tradeSeq analysis depicts continuous changes in gene expression of HSPC-related genes (DLK1, ADGRG6), and provides a roadmap of gene expression at the earliest branching points. We identify CD273/PD-L2 to be highly expressed in a subfraction of immature multipotent HSPCs with enhanced quiescence. Functional experiments confirm the immune-modulatory function of CD273/PD-L2 on HSPCs in regulating T-cell activation and cytokine release. Here, we present a molecular map of early HSPC differentiation across human life. Therapeutic application of hematopoietic stem cells requires a thorough understanding of their in situ differentiation pathways. Here they use single cell proteo-transcriptomic sequencing to identify human HSPC differentiation cues and an immunoregulatory function of CD273/PD-L2 on early HSPCs.
Related Products
Related Products
Quality Statement:
PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED. FOR ADDITIONAL INFORMATION ON QUALITY AT STEMCELL, REFER TO WWW.STEMCELL.COM/COMPLIANCE.
PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED. FOR ADDITIONAL INFORMATION ON QUALITY AT STEMCELL, REFER TO WWW.STEMCELL.COM/COMPLIANCE.
